VHL disease and kidney tumor risk study
Part of Brain & nervous system, Cancer, Genetic & congenital, Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how early changes in kidney cells can lead to tumors in people with VHL disease. It may help understand why some people develop kidney cancer and how to prevent it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a genetic diagnosis of VHL disease
- You are between 25 and 65 years old
- You have not had both kidneys removed
- You are not on dialysis or have had a kidney transplant
- You are not taking any medications that can harm the kidneys
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have von Hippel-Lindau (VHL) over time to better understand how the condition changes. It may help doctors plan future treatments by collecting long-term health information.
This study is for people with von Hippel-Lindau (vHL) disease to collect information for research. It may help researchers better understand the condition and how to care for people with it.
This study looks back at the health records of children with Von Hippel-Lindau disease to understand how the condition progresses and to find factors that predict long-term outcomes. It focuses on hemangioblastomas in the brain and spinal cord, which are non-cancerous tumors.
This trial focuses on checking whether a specific inner-ear tumor (called an endolymphatic sac tumor) can be found earlier in people with Von Hippel-Lindau (vHL) disease. It may help doctors detect problems sooner so you can discuss treatment options earlier, if needed.
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
This trial tests a new drug called HS-10516 in people with VHL syndrome or advanced kidney cancer. The goal is to see if the drug can shrink tumors and what side effects it might have.
Hear when a new Von Hippel-Lindau Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.